ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal second quarter, ended December 31, 2018.
CSI’s second-quarter revenues were $60.2 million, an increase of $7.6 million, or 14.4%, from the second quarter of fiscal 2018. Gross profit margin remained healthy at 80.9%, but declined modestly compared to last year due to increased revenues from international distributors, and domestic sales of coronary balloons and peripheral guidewires.
Selling, general and administrative expenses increased 11.1% to $41.1 million due to increased investments to support international expansion. Research and development expenses increased 13.2% to $7.2 million as a result of planned new product development and patient enrollment costs in the ECLIPSE clinical trial.
Second-quarter net income was $0.5 million, or $0.01 per basic and diluted share, compared to a net loss of $0.4 million, or $0.01 per basic share, in the prior-year period. Adjusted EBITDA totaled $4.0 million.
Scott Ward, CSI’s Chairman, President and Chief Executive Officer, said, “We are driving market leading performance with orbital atherectomy and we are executing on our key growth initiatives to introduce new products and launch our business in new markets around the world.”
Distribution Partner OrbusNeich Launched Orbital Atherectomy in Several New Geographies
- In November, CSI announced the first patient in Hong Kong was treated with the Diamondback 360® Coronary Orbital Atherectomy System (OAS), representing the first international coronary procedure as a result of the company’s distribution agreement with OrbusNeich.
- In November, the first patients in Germany were treated with the Stealth 360® Peripheral OAS, representing the first commercial use of Peripheral OAS in Europe.
- In January, the first patients in the United Arab Emirates were treated with the Diamondback 360® Coronary OAS, representing the first use of OAS in the Middle East.
Diamondback 360® Coronary OAS with
Classic Crown and ViperWire Advance® FlexTip
Guidewire Approved in Japan
On January 2, CSI announced that
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved the
Diamondback 360® Coronary OAS with Classic
Crown (Classic Crown) and ViperWire Advance®
Coronary Guidewire FlexTip (FlexTip).
Classic Crown is the market-leading coronary atherectomy device in the United States. Classic Crown utilizes a 1.25mm eccentrically mounted diamond-coated crown and a patented combination of centrifugal force and differential sanding to safely modify arterial calcium. This device now features GlideAssist®, which allows for tracking, easier removal and smoother repositioning of the device – particularly in challenging anatomies.
FlexTip is a unique new atherectomy guidewire with a nitinol core and shapeable stainless-steel tip for increased flexibility and kink-resistance, improved navigation, and reduced guidewire bias in complex coronary vessels.
Said Ward, “Continuous innovation in our core technology is a priority at CSI. With the simultaneous launch of Classic Crown, GlideAssist and FlexTip, physicians in Japan now have access to a full range of new technologies that will improve the quality of care for patients with complex and calcified coronary artery disease.”
First Patients in United States Treated with OrbusNeich Teleport®
Microcatheter
In December, CSI announced that the first
patients in the United States were treated using the OrbusNeich® Teleport
Microcatheter (Teleport), which recently received U.S. Food and Drug
Administration (FDA) 510(k) clearance.
Microcatheters are used to provide support and safe guidewire exchange during complex cardiovascular procedures. Teleport is a new generation microcatheter designed for deliverability and support, with a unique and robust tip designed to enable access in the most challenging lesions.
Said Ward, “We are committed to building a comprehensive cardiovascular company and leveraging our commercial footprint and clinical value to become the partner of choice in the revascularization of patients with complex peripheral and coronary artery disease. The clearance of the Teleport Microcatheter complements our emphasis on providing advanced solutions for the most difficult coronary and peripheral lesions.”
Company Updates Fiscal 2019 Guidance
Ward concluded,
“Revenues grew 13.8% during the first half of fiscal 2019. Our key
revenue drivers came in on plan; domestic atherectomy grew 10% and we
added $4.2 million in new revenue from international distributors and
the domestic sale of OrbusNeich angioplasty balloons and ZILIENT™
guidewires. We anticipate similar contributions from these drivers
during the second half of fiscal 2019. As a result, we remain on track
to achieve the midpoint of our fiscal 2019 revenue guidance range.
“In conjunction with our pre-announcement of second quarter revenue results on January 7, we narrowed our fiscal 2019 revenue expectations to a range of $243 million to $247 million from a range of $240 million to $250 million. Our gross margin and profitability expectations for fiscal 2019 remain consistent with the financial guidance we provided at our analyst day meeting on July 31, 2018.”
For the fiscal 2019 ending June 30, 2019, CSI anticipates:
- Revenue in a range of $243 million to $247 million;
- Gross profit as a percentage of revenues of about 80%;
- Net loss equal to 1%-2% of revenue; and
- Positive Adjusted EBITDA.
Conference Call Scheduled for Today at 3:30 p.m. CT (4:30 p.m. ET)
Cardiovascular
Systems, Inc. will host a live conference call and webcast of its fiscal
second-quarter results today, January 30, 2019, at 3:30 p.m. CT (4:30
p.m. ET). To access the call, dial (833) 241-7255 and enter the access
number 7499798. Please dial in at least 10 minutes prior to the call. To
access the live webcast, go to the events section of the company’s
investor relations website, https://investors.csi360.com/events-and-presentations/events-calendar/default.aspx,
and click on the webcast link.
Use of Non-GAAP Financial Measures
To supplement CSI's
consolidated condensed financial statements prepared in accordance with
U.S. generally accepted accounting principles (GAAP), CSI uses certain
non-GAAP financial measures in this release. Reconciliations of the
non-GAAP financial measures used in this release to the most comparable
U.S. GAAP measures for the respective periods can be found in tables
later in this release immediately following the consolidated statements
of operations. Non-GAAP financial measures have limitations as
analytical tools and should not be considered in isolation or as a
substitute for CSI's financial results prepared in accordance with GAAP.
About Peripheral Artery Disease (PAD)
As many as 18 million
Americans, most over age 65, suffer from PAD, which is caused by the
accumulation of plaque in peripheral arteries reducing blood flow.
Symptoms include leg pain when walking or at rest. Left untreated, PAD
can lead to severe pain, immobility, non-healing wounds and eventually
limb amputation. With risk factors such as diabetes and obesity on the
rise, the prevalence of PAD is growing at double-digit rates.
Millions of patients with PAD may benefit from treatment with orbital atherectomy utilizing the Stealth 360® and Diamondback 360® Peripheral Orbital Atherectomy Systems, minimally invasive catheter systems developed and manufactured by CSI. These systems use a diamond-coated crown, attached to an orbiting shaft, which sands away plaque while preserving healthy vessel tissue — a critical factor in preventing reoccurrences. Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions. Stents are prone to fractures and high recurrence rates, and treatment of hard, calcified lesions often leads to vessel damage and suboptimal results.
About Coronary Artery Disease (CAD)
CAD is a
life-threatening condition and a leading cause of death in men and women
in the United States. CAD occurs when a fatty material called plaque
builds up on the walls of arteries that supply blood to the heart. The
plaque buildup causes the arteries to harden and narrow
(atherosclerosis), reducing blood flow. The risk of CAD increases if a
person has one or more of the following: high blood pressure, abnormal
cholesterol levels, diabetes, or family history of early heart disease.
According to the American Heart Association, 16.3 million people in the
United States have been diagnosed with CAD, the most common form of
heart disease. Heart disease claims more than 600,000 lives in the
United States each year. According to estimates, significant arterial
calcium is present in nearly 40% of patients undergoing a percutaneous
coronary intervention (PCI). Significant calcium contributes to poor
outcomes and higher treatment costs in coronary interventions when
traditional therapies are used, including a significantly higher
occurrence of death and major adverse cardiac events (MACE).
About Cardiovascular Systems, Inc.
Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused on
developing and commercializing innovative solutions for treating
vascular and coronary disease. The company’s Orbital Atherectomy Systems
treat calcified and fibrotic plaque in arterial vessels throughout the
leg and heart in a few minutes of treatment time, and address many of
the limitations associated with existing surgical, catheter and
pharmacological treatment alternatives. The U.S. FDA granted 510(k)
clearance for the use of the Diamondback Orbital Atherectomy System in
peripheral arteries in August 2007. In October 2013, the company
received FDA approval for the use of the Diamondback Orbital Atherectomy
System in coronary arteries. The Stealth 360® Peripheral
Orbital Atherectomy System (OAS) received CE Mark in October 2014. In
March 2017, the company received PMDA approval in Japan for the
Diamondback 360® Coronary OAS Micro Crown and
reimbursement approval effective February 2018. Over 400,000 of CSI’s
devices have been sold to leading institutions worldwide. For more
information, visit the company’s website at www.csi360.com.
About OrbusNeich
OrbusNeich® is a
global pioneer in the provision of life-changing vascular solutions and
offers an extensive portfolio of products that set industry benchmarks
in vascular intervention. Current products include the world's first
dual therapy stents, the COMBO® Plus and COMBO®
Dual Therapy Stents, together with stents, balloons and microcatheters
marketed under the names of Azule®, Scoreflex®,
Sapphire® II, Sapphire® II
PRO, Sapphire® II NC, Teleport®
and Teleport® Control as well as products to treat
peripheral artery disease: the Jade® and
Scoreflex® PTA balloons. OrbusNeich is
headquartered in Hong Kong and has operations in Shenzhen, China; Fort
Lauderdale, Florida, USA; Hoevelaken, The Netherlands; and Tokyo, Japan.
OrbusNeich supplies medical devices to physicians in more than 60
countries. For more information, visit www.OrbusNeich.com.
Safe Harbor
Certain statements in this news release are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and are provided under the protection of
the safe harbor for forward-looking statements provided by that Act. For
example, statements in this press release regarding (i) CSI’s
anticipated introduction of new products and launching its business in
new markets around the world; (ii) the introduction of Classic Crown,
GlideAssist and FlexTip in Japan; (iii) CSI’s commitment to building a
comprehensive cardiovascular company and leveraging its commercial
footprint and clinical value; (iv) revenue growth in the second half of
fiscal 2019 and the factors driving such growth; and (v) anticipated
revenue, gross profit, net loss and Adjusted EBITDA, are forward-looking
statements. These statements involve risks and uncertainties that could
cause results to differ materially from those projected, including, but
not limited to, regulatory developments, clearances and approvals;
approval of our products for distribution in countries outside of the
United States; approval of products for reimbursement and the level of
reimbursement in the U.S., Japan and other foreign countries; dependence
on market growth; agreements with third parties to sell their products;
the ability of OrbusNeich to successfully launch CSI products outside of
the United States and Japan; our ability to maintain third-party
supplier relationships and renew existing purchase agreements; our
ability to maintain our relationship with our distribution partner in
Japan and with OrbusNeich; the experience of physicians regarding the
effectiveness and reliability of the products we sell; the reluctance of
physicians, hospitals and other organizations to accept new products;
the potential for unanticipated delays in enrolling medical centers and
patients for clinical trials; actual clinical trial and study results;
the impact of competitive products and pricing; unanticipated
developments affecting our estimates regarding expenses, future revenues
and capital requirements; the difficulty of successfully managing
operating costs; our ability to manage our sales force strategy; our
actual research and development efforts and needs; our ability to obtain
and maintain intellectual property protection for product candidates;
our actual financial resources and our ability to obtain additional
financing; fluctuations in results and expenses based on new product
introductions, sales mix, unanticipated warranty claims, and the timing
of project expenditures; our ability to manage costs; investigations or
litigation threatened or initiated against us; court rulings and future
actions by the FDA and other regulatory bodies; the effects of
hurricanes, flooding, and other natural disasters on our business;
issues relating to our saline pump recall; the impact of federal
corporate tax reform on our business, operations and financial
statements; international trade developments; shutdowns of the U.S.
federal government; general economic conditions; and other factors
detailed from time to time in CSI’s SEC reports, including its most
recent annual report on Form 10-K and subsequent quarterly reports on
Form 10-Q. CSI encourages you to consider all of these risks,
uncertainties and other factors carefully in evaluating the
forward-looking statements contained in this release. As a result of
these matters, changes in facts, assumptions not being realized or other
circumstances, CSI's actual results may differ materially from the
expected results discussed in the forward-looking statements contained
in this release. The forward-looking statements made in this release are
made only as of the date of this release, and CSI undertakes no
obligation to update them to reflect subsequent events or circumstances.
Product Disclosures:
Peripheral Products
The Stealth 360® PAD System
and Diamondback 360® PAD System are percutaneous orbital
atherectomy systems indicated for use as therapy in patients with
occlusive atherosclerotic disease in peripheral arteries and stenotic
material from artificial arteriovenous dialysis fistulae. The systems
are contraindicated for use in coronary arteries, bypass grafts, stents
or where thrombus or dissections are present. Although the incidence of
adverse events is rare, potential events that can occur with atherectomy
include: pain, hypotension, CVA/TIA, death, dissection, perforation,
distal embolization, thrombus formation, hematuria, abrupt or acute
vessel closure, or arterial spasm. See the instructions for use for
detailed information regarding the procedure, indications,
contraindications, warnings, precautions, and potential adverse events.
For further information call CSI at 1-877-274-0901 and/or consult CSI’s
website at www.csi360.com.
Coronary Product
Indications: The Diamondback 360®
Coronary Orbital Atherectomy System (OAS) is a percutaneous orbital
atherectomy system indicated to facilitate stent delivery in patients
with coronary artery disease (CAD) who are acceptable candidates for
PTCA or stenting due to de novo, severely calcified coronary
artery lesions.
Contraindications: The OAS is contraindicated when the ViperWire® guide wire cannot pass across the coronary lesion or the target lesion is within a bypass graft or stent. The OAS is contraindicated when the patient is not an appropriate candidate for bypass surgery, angioplasty, or atherectomy therapy, or has angiographic evidence of thrombus, or has only one open vessel, or has angiographic evidence of significant dissection at the treatment site and for women who are pregnant or children.
Warnings/Precautions: Performing treatment in excessively tortuous vessels or bifurcations may result in vessel damage; The OAS was only evaluated in severely calcified lesions, A temporary pacing lead may be necessary when treating lesions in the right coronary and circumflex arteries; On-site surgical back-up should be included as a clinical consideration; Use in patients with an ejection fraction (EF) of less than 25% has not been evaluated. See the instructions for use before performing Diamondback 360 Coronary OAS procedures for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information call CSI at 1-877-274-0901 and/or consult CSI’s website at www.csi360.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
| Cardiovascular Systems, Inc. | ||||||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||||||
| (Dollars in Thousands) | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||||||
|
December 31 |
December 31 |
|||||||||||||||||||
|
2018 |
2017 |
2018 |
2017 |
|||||||||||||||||
| Net revenues | $ | 60,206 | $ | 52,628 | $ | 116,472 | $ | 102,304 | ||||||||||||
| Cost of goods sold | 11,477 | 9,499 | 22,052 | 18,701 | ||||||||||||||||
| Gross profit | 48,729 | 43,129 | 94,420 | 83,603 | ||||||||||||||||
| Expenses: | ||||||||||||||||||||
| Selling, general and administrative | 41,107 | 37,008 | 82,349 | 72,926 | ||||||||||||||||
| Research and development | 7,238 | 6,396 | 14,655 | 12,704 | ||||||||||||||||
| Total expenses | 48,345 | 43,404 | 97,004 | 85,630 | ||||||||||||||||
| Income (loss) from operations | 384 | (275 | ) | (2,584 | ) | (2,027 | ) | |||||||||||||
| Other (income) and expense, net | (141 | ) | 105 | (254 | ) | 297 | ||||||||||||||
| Income (loss) before income taxes | 525 | (380 | ) | (2,330 | ) | (2,324 | ) | |||||||||||||
| Provision for income taxes | 33 | 33 | 66 | 66 | ||||||||||||||||
| Net income (loss) | $ | 492 | $ | (413 | ) | $ | (2,396 | ) | $ | (2,390 | ) | |||||||||
|
Basic earnings per share |
$ | 0.01 | $ | (0.01 | ) | $ | (0.07 | ) | $ | (0.07 | ) | |||||||||
| Diluted earnings per share | $ | 0.01 | $ | (0.01 | ) | $ | (0.07 | ) | $ | (0.07 | ) | |||||||||
| Basic weighted average shares outstanding | 33,507,843 | 33,112,138 | 33,466,454 | 33,040,425 | ||||||||||||||||
| Diluted weighted average shares outstanding | 34,120,639 | 33,112,138 | 33,466,454 | 33,040,425 | ||||||||||||||||
| Cardiovascular Systems, Inc. | ||||||||
| Consolidated Balance Sheets | ||||||||
| (Dollars in Thousands) | ||||||||
| (unaudited) | ||||||||
|
December 31, |
June 30, |
|||||||
|
2018 |
2018 |
|||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 118,772 | $ | 116,260 | ||||
| Accounts receivable, net | 29,906 | 31,225 | ||||||
| Inventories | 19,679 | 16,605 | ||||||
| Marketable securities | 434 | 544 | ||||||
| Prepaid expenses and other current assets | 1,944 | 2,977 | ||||||
| Total current assets | 170,735 | 167,611 | ||||||
| Property and equipment, net | 28,230 | 27,744 | ||||||
| Patents, net | 5,307 | 5,231 | ||||||
| Other assets | 2,915 | 2,766 | ||||||
| Total assets | $ | 207,187 | $ | 203,352 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 12,998 | $ | 10,441 | ||||
| Accrued expenses | 24,472 | 25,776 | ||||||
| Deferred revenue | 1,519 | 1,243 | ||||||
| Total current liabilities | 38,989 | 37,460 | ||||||
| Long-term liabilities | ||||||||
| Finance obligation | 21,025 | 21,064 | ||||||
| Deferred revenue | 7,700 | 8,946 | ||||||
| Other liabilities | 875 | 1,412 | ||||||
| Total liabilities | 68,589 | 68,882 | ||||||
| Commitments and contingencies | - | - | ||||||
| Total stockholders' equity | 138,598 | 134,470 | ||||||
| Total liabilities and stockholders' equity | $ | 207,187 | $ | 203,352 | ||||
Non-GAAP Financial Measures
To supplement CSI's consolidated
condensed financial statements prepared in accordance with GAAP, CSI
uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in
this release.
Reconciliations of this non-GAAP measure to the most comparable U.S. GAAP measure for the respective periods can be found in the following tables. In addition, an explanation of the manner in which CSI's management uses this measure to conduct and evaluate its business, the economic substance behind management's decision to use this measure, the substantive reasons why management believes that this measure provides useful information to investors, the material limitations associated with the use of this measure and the manner in which management compensates for those limitations is included following the reconciliation table.
| Adjusted EBITDA | ||||||||||||||||||||
| (Dollars in Thousands) | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||
| December 31 | December 31 | |||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||||
| Net income (loss) | $ | 492 | $ | (413 | ) | $ | (2,396 | ) | $ | (2,390 | ) | |||||||||
| Less: Other (income) and expense, net | (141 | ) | 105 | (254 | ) | 297 | ||||||||||||||
| Less: Provision for income taxes | 33 | 33 | 66 | 66 | ||||||||||||||||
| Income (loss) from operations | 384 | (275 | ) | (2,584 | ) | (2,027 | ) | |||||||||||||
| Add: Stock-based compensation | 2,770 | 2,670 | 5,926 | 5,740 | ||||||||||||||||
| Add: Depreciation and amortization | 831 | 1,047 | 1,685 | 2,090 | ||||||||||||||||
| Adjusted EBITDA | $ | 3,985 | $ | 3,442 | $ | 5,027 | $ | 5,803 | ||||||||||||
Use and Economic Substance of Non-GAAP Financial Measures Used by CSI
and Usefulness of Such Non-GAAP Financial Measures to Investors
CSI
uses Adjusted EBITDA as a supplemental measure of performance and
believes this measure facilitates operating performance comparisons from
period to period and company to company by factoring out potential
differences caused by depreciation and amortization expense and non-cash
charges such as stock based compensation. CSI's management uses Adjusted
EBITDA to analyze the underlying trends in CSI's business, assess the
performance of CSI's core operations, establish operational goals and
forecasts that are used to allocate resources and evaluate CSI's
performance period over period and in relation to its competitors'
operating results. Additionally, CSI's management is evaluated on the
basis of Adjusted EBITDA when determining achievement of their incentive
compensation performance targets.
CSI believes that presenting Adjusted EBITDA provides investors greater transparency to the information used by CSI's management for its financial and operational decision-making and allows investors to see CSI's results "through the eyes" of management. CSI also believes that providing this information better enables CSI's investors to understand CSI's operating performance and evaluate the methodology used by CSI's management to evaluate and measure such performance.
The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items:
- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financial measures primarily because such expense, while constituting an ongoing and recurring expense, is not an expense that requires cash settlement. CSI's management also believes that excluding this item from CSI's non-GAAP results is useful to investors to understand the application of stock-based compensation guidance and its impact on CSI's operational performance, liquidity and its ability to make additional investments in the company, and it allows for greater transparency to certain line items in CSI's financial statements.
- Depreciation and amortization expense. CSI excludes depreciation and amortization expense from its non-GAAP financial measures primarily because such expenses, while constituting ongoing and recurring expenses, are not expenses that require cash settlement and are not used by CSI's management to assess the core profitability of CSI's business operations. CSI's management also believes that excluding these items from CSI's non-GAAP results is useful to investors to understand CSI's operational performance, liquidity and its ability to make additional investments in the company.
Material Limitations Associated with the Use of Non-GAAP Financial Measures and Manner in which CSI Compensates for these Limitations
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for CSI's financial results prepared in accordance with GAAP. Some of the limitations associated with CSI's use of these non-GAAP financial measures are:
- Items such as stock-based compensation do not directly affect CSI's cash flow position; however, such items reflect economic costs to CSI and are not reflected in CSI's "Adjusted EBITDA" and therefore these non-GAAP measures do not reflect the full economic effect of these items.
- Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than CSI, limiting the usefulness of those measures for comparative purposes.
- CSI's management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures CSI uses. CSI compensates for these limitations by relying primarily upon its GAAP results and using non-GAAP financial measures only supplementally. CSI provides full disclosure of each non-GAAP financial measure.
- CSI uses and detailed reconciliations of each non-GAAP measure to its most directly comparable GAAP measure. CSI encourages investors to review these reconciliations. CSI qualifies its use of non-GAAP financial measures with cautionary statements as set forth above.